Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their target price on shares of Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday.

Aptose Biosciences Stock Down 22.1 %

NASDAQ:APTO opened at $0.19 on Thursday. Aptose Biosciences has a 52-week low of $0.13 and a 52-week high of $2.91. The stock has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.61. The company has a market capitalization of $3.44 million, a PE ratio of -0.06 and a beta of 1.26.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp boosted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.